Infectious Disease Vaccine

Pneumococcal Surface Adhesin Shows Promise

Published in Medical Letter on the CDC and FDA, February 24th, 2002

by Michael Greer, senior medical writer - Researchers in the United States say that a pneumcoccal protein can induce potent antibacterial immune responses.

"Pneumococcal surface adhesin A (PsaA), a common protein expressed on all 90 pneumococcal serotypes, is a vaccine candidate," explained Dr. Scott E. Johnson and colleagues at the U.S. Centers for Disease Control and Prevention in Atlanta, Georgia.

PsaA peptides were highly immunogenic in a murine model, Johnson and coauthors reported.

The researchers evaluated the efficacy of three PsaA peptides in mice exposed to pneumococcal pathogens. They tested the effects of lipidating...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (2002-02-24)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry